Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 207

Similar articles for PubMed (Select 13679386)

1.

The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization.

Haicheur N, Benchetrit F, Amessou M, Leclerc C, Falguières T, Fayolle C, Bismuth E, Fridman WH, Johannes L, Tartour E.

Int Immunol. 2003 Oct;15(10):1161-71.

2.

The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.

Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P, Goud B, Fridman WH, Johannes L, Tartour E.

J Immunol. 2000 Sep 15;165(6):3301-8.

3.

B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.

Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, Fridman WH, Lemonnier F, Johannes L, Tartour E.

J Immunol. 2007 Sep 1;179(5):3371-9.

4.

The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.

Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M, Quintin-Colonna F, Fridman WH, Johannes L, Tartour E.

Eur J Immunol. 2006 May;36(5):1124-35.

PMID:
16568496
6.

Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.

Mitsui H, Okamoto T, Kanzaki M, Inozume T, Shibagaki N, Shimada S.

Br J Dermatol. 2010 Jan;162(1):29-41. doi: 10.1111/j.1365-2133.2009.09490.x. Epub 2009 Oct 26.

PMID:
19863514
8.
9.

Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.

Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.

Clin Cancer Res. 1999 May;5(5):1173-82.

10.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.

Cancer Immunol Immunother. 2004 Nov;53(11):963-77. Epub 2004 May 14.

PMID:
15146294
11.
12.

Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin.

Lee RS, Tartour E, van der Bruggen P, Vantomme V, Joyeux I, Goud B, Fridman WH, Johannes L.

Eur J Immunol. 1998 Sep;28(9):2726-37.

PMID:
9754560
13.

Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.

Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T.

Vaccine. 2005 Jan 26;23(10):1232-41.

PMID:
15652665
14.

Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway.

Garg N, Nunes MP, Tarleton RL.

J Immunol. 1997 Apr 1;158(7):3293-302.

PMID:
9120286
15.

Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.

Yokouchi H, Chamoto K, Wakita D, Noguchi D, Yamazaki K, Dosaka-Akita H, Nishimura M, Ikeda H, Nishimura T.

Cancer Sci. 2006 Feb;97(2):148-54.

PMID:
16441426
16.
17.
18.
19.

Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells.

Tagliani E, Guermonprez P, Sepúlveda J, López-Bravo M, Ardavín C, Amigorena S, Benvenuti F, Burrone OR.

J Immunol. 2008 Mar 1;180(5):3201-9.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk